title: The 2012 hormone therapy position statement of: The North American Menopause Society.
abstract: OBJECTIVE
  This position statement aimed to update the evidence-based position statement published by The North American Menopause Society (NAMS) in 2010 regarding recommendations for hormone therapy (HT) for postmenopausal women. This updated position statement further distinguishes the emerging differences in the therapeutic benefit-risk ratio between estrogen therapy (ET) and combined estrogen-progestogen therapy (EPT) at various ages and time intervals since menopause onset.
  
  
  METHODS
  An Advisory Panel of expert clinicians and researchers in the field of women's health was enlisted to review the 2010 NAMS position statement, evaluate new evidence, and reach consensus on recommendations. The Panel's recommendations were reviewed and approved by the NAMS Board of Trustees as an official NAMS position statement.
  
  
  RESULTS
  Current evidence supports the use of HT for perimenopausal and postmenopausal women when the balance of potential benefits and risks is favorable for the individual woman. This position statement reviews the effects of ET and EPT on many aspects of women's health and recognizes the greater safety profile associated with ET.
  
  
  CONCLUSIONS
  Recent data support the initiation of HT around the time of menopause to treat menopause-related symptoms and to prevent osteoporosis in women at high risk of fracture. The more favorable benefit-risk ratio for ET allows more flexibility in extending the duration of use compared with EPT, where the earlier appearance of increased breast cancer risk precludes a recommendation for use beyond 3 to 5 years.
mesh_terms: D001943:Breast Neoplasms / Q000139:chemically induced; D002277:Carcinoma / Q000139:chemically induced; D004967:Estrogens / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D050723:Fractures, Bone / Q000517:prevention & control; D020249:Hormone Replacement Therapy / Q000009:adverse effects*; D006801:Humans; D010024:Osteoporosis / Q000517:prevention & control; D047648:Perimenopause / Q000187:drug effects; D017698:Postmenopause / Q000187:drug effects; D011372:Progestins / Q000009:adverse effects / Q000627:therapeutic use; D012306:Risk
chemical_list: D004967:Estrogens; D011372:Progestins